Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
Read more -
GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer
Data accepted as a late-breaking abstract and presented as a webinar as part of the Society of Gynecologic Oncology 2020 virtual congress
Read more -
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine.
Read more -
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks.
Read more -
Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
Pivotal data support regulatory filing for additional eosinophil-driven disease
Read more -
GSK completes divestment of Horlicks and other Consumer Healthcare nutrition products in India and certain other markets
GSK today announced the completion of its divestment of Horlicks and other Consumer Healthcare nutrition products in India to Unilever.
Read more -
GSK appoints Charles Bancroft to the Board as a Non-Executive Director
GlaxoSmithKline plc today announced that Charles Bancroft will join the Board of the Company as a Non-Executive Director on 1 May 2020.
Read more -
ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV
ViiV Healthcare, today announced that Health Canada has approved CABENUVA.
Read more -
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1
ViiV Healthcare presents positive long-term data from phase III study
Read more -
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
ViiV Healthcare presents positive 48-week data from phase III study
Read more -
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
Read more -
GSK receives EC approval for the sale of ThermaCare
GSK receives EC approval for the sale of ThermaCare
Read more -
FDA approves GSK’s Advil Dual Action with Acetaminophen for over-the-counter use in the United States
First combination of ibuprofen and acetaminophen for pain relief to be available OTC in 2020
Read more -
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
Read more -
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
Read more -
European Medicines Agency accepts submission of GSK’s Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Submission based on data from the Phase III PRIMA clinical study.
Read more -
U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib)
Read more -
Clover and GSK announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with pandemic adjuvant system
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
Read more -
FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States
U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain as an over-the-counter (OTC) product.
Read more -
GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)
Total EPS 93.9p; +27% AER; +23% CER; Adjusted EPS 123.9p +4% AER, +1% CER
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
